Appajosyula Sireesh 4

What Happened Sireesh Appajosyula, a director of Hepion Pharmaceuticals, reported a purchase of 1,250,000 shares on 2026-04-21. The transaction was reported as a purchase (code P) at $0.04 per share, for a total cash outlay of $50,000. This was an outright buy (open market or private purchase as listed on the Form 4).

Key Details

• Transaction date: 2026-04-21; Report filed: 2026-04-27 (see note on timeliness below)
• Price per share: $0.04; Shares acquired: 1,250,000; Total value: $50,000
• Transaction type: P = Purchase (open market or private purchase)
• Shares owned after transaction: not specified in the provided filing details
• Footnotes/plan: none noted in the provided data
• Filing timeliness: Form 4 was filed six days after the transaction, which exceeds the usual two-business-day reporting deadline for insiders

Context Insider purchases can be viewed as a potentially bullish signal because they involve insiders committing personal capital, but they are one data point and not proof of future company performance. This report involves a direct share purchase rather than an option exercise or award, and there is no indication here of a 10b5-1 plan or immediate resale. The late filing is a procedural issue to note — late Form 4s can draw regulatory attention but do not by themselves explain the insider's motivation.